Does the menopausal transition increase abdominal fat and reduce insulin sensitivity?

During the menopausal transition, women experience significant endocrine and metabolic changes that independently alter body composition and metabolic health.

Clinical and effectiveness evidence

• Accelerated abdominal adiposity: Longitudinal data from the Study of Women’s Health Across the Nation (SWAN), using computed tomography (CT) and dual-energy X-ray absorptiometry (DXA), demonstrate a rapid redistribution of fat toward the trunk and visceral cavities during the menopausal transition. This shift occurs independently of chronological aging.
• Declining insulin sensitivity: Longitudinal cohort assessments show a significant rise in the homeostatic model assessment of insulin resistance (HOMA-IR) as women transition from premenopause to postmenopause. This progression remains statistically significant after adjusting for age, ethnicity, and changes in total body weight.

Mechanistic explanations

• Estrogen deficiency and fat partitioning: Estradiol normally promotes subcutaneous lipid storage in the gluteofemoral depot by signaling through estrogen receptor alpha (ERα). The decline in estradiol levels during menopause impairs subcutaneous storage capacity, redirecting lipids toward visceral adipose tissues.
• Adipose tissue dysfunction: The loss of ERα signaling in visceral fat triggers adipocyte hypertrophy, suppresses mitochondrial thermogenesis, and promotes low-grade tissue inflammation characterized by protective regulatory T-cell depletion.
• Interconnected metabolic pathways: The accumulation of central (visceral) fat directly drives systemic insulin resistance. Visceral adipose tissue releases elevated levels of free fatty acids and pro-inflammatory cytokines into the portal circulation, impairing hepatic and peripheral insulin sensitivity.

Bottom line

• The menopausal transition is directly associated with increased central (abdominal) fat accumulation and reduced insulin sensitivity. These changes are driven by progressive estrogen decline and subsequent adverse shifts in adipose tissue distribution and function, operating independently of chronological aging.